自动化和封闭式细胞治疗处理系统市场－全球产业规模、份额、趋势、机会、预测：按工作流程、类型、规模、地区和竞争格局划分，2021-2031年

全球自动化闭式细胞治疗处理系统市场预计将从 2025 年的 9.3108 亿美元成长到 2031 年的 15.9359 亿美元，复合年增长率达到 9.37%。

这些系统作为一个整合平台，可在密封环境中分离、浓缩、培养和收穫治疗性细胞，有效降低污染风险并减少人工干预。推动该市场发展的关键因素包括：为满足日益增长的先进治疗方法需求，迫切需要可扩展的生产解决方案；以及符合良好生产规范 (GMP) 的严格监管要求。根据美国基因与细胞治疗学会 (ASGCT) 预测，到 2024 年，全球将有超过 4000 种基于基因、细胞和 RNA 的治疗方法处于研发阶段，这凸显了高效加工技术对于支持这一庞大临床研发管线的重要性。

然而，该市场面临许多挑战，因为实施这些系统需要大量的资本投入，而中小企业往往难以承担向全自动化工作流程转型所需的成本。此外，这些系统的技术复杂性也构成了进入门槛，需要高度专业化的人员才能有效地运作和维护这些基础设施。

市场驱动因素

全球细胞和基因疗法研发管线的快速扩张，正大幅推动自动化闭环处理系统的应用。随着製药公司将候选药物从研发阶段推进到后期临床试验和商业化生产阶段，对能够确保无菌性和扩充性的设施的需求也随之激增。根据再生医学联盟的数据，截至2024年1月，全球约有1900项临床试验正在进行，显示大量潜在治疗方法需要标准化的生产基础设施。这种研发管线的扩张与商业性现实直接相关，因此迫切需要能够在不影响品质的前提下支援高通量生产的平台。根据《细胞与基因疗法评论》报道，截至2024年11月，美国FDA已核准了7种新的细胞和基因疗法，这一趋势凸显了市场向商业化可行的自动化处理解决方案转变的重要性。

同时，由于迫切需要降低生产和营运成本，製药业正被迫摒弃劳力密集的手工工作流程。传统的开放式生产方法高度依赖熟练的操作人员，并且需要大规模无尘室设施，因此成本极为高。自动化封闭式系统透过显着降低销货成本和提高批次一致性，消除了这些经济瓶颈。据 Cellares 公司称，截至 2024 年 3 月，其符合 cGMP 标准的自动化生产平台与传统的手动流程相比，已将人事费用和设施规模需求降低了 90%。透过最大限度地减少人为干预和面积，这些系统使製造商能够实现满足全球日益增长的患者需求所需的扩充性和经济可行性。

市场挑战

自动化闭环细胞治疗处理系统的实施需要大量的资本投入，这成为市场扩张的主要障碍。这些整合平台需要大量的初期投资，不仅包括设备成本，还包括设施整合和合格费用。对于通常引领该领域创新的中小企业而言，这种财务负担可能构成障碍。因此，许多潜在用户被迫依赖成本较低的人工处理方法，这限制了自动化解决方案的即时基本客群，并减缓了市场渗透的整体速度。

鑑于产业现状，这些资金限制尤为严峻。根据再生医学联盟统计，截至2024年，全球整体约有3,000家研发营业单位从事该领域的工作。其中大多数是资金有限的新兴生技公司，难以承担向昂贵的自动化基础设施转型所带来的成本。这一关键领域无法采用先进的加工系统，直接限制了製造商的销售量。此外，大型企业严格的资本核准流程也减缓了技术的普及，阻碍了市场的发展。

市场趋势

合约研发生产机构 (CDMO) 对自动化平台的策略性采用，标誌着市场商业结构的根本性转变。 CDMO 正在增加对多功能封闭式系统技术的投资，以确保从领先的製药研发公司获得长期产能，从而实现不同治疗方法方式的标准化生产。这一趋势正引领产业走向一种新的模式：产能不再完全依赖内部建设，而是可以透过第三方合作伙伴灵活快速地扩展。据 Cellares 公司称，该公司于 2024 年 4 月与百时美施贵宝公司签署了一项价值高达 3.8 亿美元的全球产能预订和供应协议，使用其自动化平台 Cell Shuttle 生产 CAR-T 细胞疗法。

同时，为了因应个人化医疗在物流方面的复杂性，分散式和照护现场生产模式正日益受到关注。透过将处理系统直接整合到医院和临床中心，相关人员旨在显着缩短从静脉到静脉的运输时间，并消除长途冷冻保存运输带来的风险。这种生产能力的在地化将治疗中心转变为生产枢纽，使患者能够立即获得新鲜的细胞产品。据MD安德森癌症中心称，该机构于2024年11月成立了“细胞疗法发现与创新研究所”，并投入超过8000万美元的资金，以加速开发和生产对临床实践具有直接影响的细胞疗法。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：自动化封闭式细胞治疗处理系统的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 工作流程分解（分离、扩增、血浆分离、填充/精製、冷冻保存、其他）
  • 依类型（干细胞疗法、非干细胞疗法）
  • 按规模（商业化前/研发规模、商业规模）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美自动化封闭式细胞治疗处理系统市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲自动化封闭式细胞治疗处理系统市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区自动化封闭式细胞治疗处理系统市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲自动化封闭式细胞治疗处理系统的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲自动化封闭式细胞治疗处理系统的市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球自动化封闭式细胞治疗处理系统市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Miltenyi Biotec BV & Co. KG
• Lonza Group AG
• Fresenius Kabi AG
• Global Life Sciences Solutions USA LLC
• BioSpherix, LLC
• Terumo Corp
• Sartorius AG
• ThermoGenesis Holdings Inc
• Cellares Corporation
• Thermo Fisher Scientific Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Automated And Closed Cell Therapy Processing Systems Market is projected to expand from USD 931.08 Million in 2025 to USD 1593.59 Million by 2031, achieving a compound annual growth rate of 9.37%. These systems function as integrated platforms designed to isolate, enrich, expand, and harvest therapeutic cells within a sealed environment, effectively minimizing contamination risks and reducing the need for manual handling. Primary drivers fueling this market include the urgent requirement for scalable manufacturing solutions to meet the rising demand for advanced therapies and the strict regulatory mandates for Good Manufacturing Practice compliance. According to the American Society of Gene & Cell Therapy, over 4,000 gene, cell, and RNA-based treatments were in research and development globally in 2024, highlighting the necessity for efficient processing technologies to support this robust clinical pipeline.

However, the market encounters a significant challenge regarding the high capital investment required for implementation, as small and medium-sized enterprises often struggle with the costs of transitioning to fully automated workflows. Furthermore, the technical complexity of these systems creates a barrier to entry, necessitating a highly specialized workforce to operate and maintain this infrastructure effectively.

Market Driver

The exponential growth in the global cell and gene therapy pipeline acts as the primary catalyst propelling the adoption of automated and closed processing systems. As pharmaceutical developers transition candidates from research settings to late-stage clinical trials and commercial production, there is a surging demand for equipment capable of ensuring sterility and scalability. Data from the Alliance for Regenerative Medicine indicates that in January 2024, there were approximately 1,900 active clinical trials globally, reflecting a massive accumulation of potential treatments requiring standardized manufacturing infrastructure. This pipeline expansion is directly translating into commercial reality, creating an urgent necessity for platforms that can support high-throughput production without compromising quality. According to the Cell & Gene Therapy Review, as of November 2024, the U.S. FDA had granted approval to seven new cell and gene therapies in 2024, a trend that underscores the critical market shift toward commercial-ready, automated processing solutions.

Simultaneously, the imperative to reduce manufacturing costs and operational overheads is driving the industry away from labor-intensive manual workflows. Traditional open processing methods are prohibitively expensive due to the high reliance on skilled operators and the need for extensive cleanroom facilities. Automated, closed systems address these economic bottlenecks by significantly lowering the cost of goods sold and enhancing batch consistency. According to Cellares, in March 2024, their cGMP-compliant automated manufacturing platform was reported to reduce labor and facility size requirements by 90% compared to conventional manual processes. By minimizing human intervention and footprint, these systems enable manufacturers to achieve the scalability and economic viability necessary to meet the growing global patient demand.

Market Challenge

The high capital investment required to implement automated and closed cell therapy processing systems acts as a significant barrier to market expansion. These integrated platforms necessitate substantial upfront expenditure, which includes the cost of the equipment as well as expenses for facility integration and qualification. For small and medium-sized enterprises, which frequently drive innovation in this sector, such financial demands can be prohibitive. Consequently, many potential adopters are forced to rely on less expensive manual processing methods, thereby limiting the immediate customer base for automated solutions and slowing the overall rate of market penetration.

This financial constraint is particularly critical given the landscape of the industry. According to the Alliance for Regenerative Medicine, in 2024, the sector encompassed approximately 3,000 developers globally. A vast majority of these entities are emerging biotechnology firms with finite financial resources, making the transition to expensive automated infrastructure difficult to justify. The inability of this substantial segment to afford advanced processing systems directly restricts sales volume for manufacturers, while the rigorous capital approval processes required by larger firms further delay implementation and hamper the market's growth trajectory.

Market Trends

The strategic adoption of automated platforms by Contract Development and Manufacturing Organizations (CDMOs) represents a fundamental shift in the market's commercial structure. CDMOs are increasingly investing in versatile, closed-system technologies to secure long-term capacity reservations from major pharmaceutical developers, thereby standardizing production across different therapeutic modalities. This trend moves the industry toward a model where manufacturing capacity is flexible and rapidly scalable through third-party partners rather than solely internal builds. According to Cellares, in April 2024, the company entered a worldwide capacity reservation and supply agreement valued at up to $380 million with Bristol Myers Squibb to manufacture CAR-T cell therapies using its automated Cell Shuttle platform.

Concurrently, the adoption of decentralized and point-of-care manufacturing models is gaining traction to address the logistical complexities of personalized treatments. By integrating processing systems directly within hospitals and clinical centers, stakeholders aim to drastically reduce vein-to-vein timelines and eliminate the risks associated with long-distance cryopreserved transport. This localization of manufacturing capability transforms treatment centers into production hubs, facilitating immediate patient access to fresh cellular products. According to MD Anderson Cancer Center, in November 2024, the institution launched its Institute for Cell Therapy Discovery & Innovation with over $80 million in funding to accelerate the development and manufacturing of impactful cell therapies directly within a clinical setting.

Key Market Players

• Miltenyi Biotec B.V. & Co. KG
• Lonza Group AG
• Fresenius Kabi AG
• Global Life Sciences Solutions USA LLC
• BioSpherix, LLC
• Terumo Corp
• Sartorius AG
• ThermoGenesis Holdings Inc
• Cellares Corporation
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Automated And Closed Cell Therapy Processing Systems Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Automated And Closed Cell Therapy Processing Systems Market, By Workflow

• Separation
• Expansion
• Apheresis
• Fill-Finish
• Cryopreservation
• Others

Automated And Closed Cell Therapy Processing Systems Market, By Type

• Stem Cell Therapy
• Non-Stem Cell Therapy

Automated And Closed Cell Therapy Processing Systems Market, By Scale

• Pre-commercial/ R&D Scale
• Commercial Scale

Automated And Closed Cell Therapy Processing Systems Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Automated And Closed Cell Therapy Processing Systems Market.

Available Customizations:

Global Automated And Closed Cell Therapy Processing Systems Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Automated And Closed Cell Therapy Processing Systems Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Separation, Expansion, Apheresis, Fill-Finish, Cryopreservation, Others)
  • 5.2.2. By Type (Stem Cell Therapy, Non-Stem Cell Therapy)
  • 5.2.3. By Scale (Pre-commercial/ R&D Scale, Commercial Scale)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Automated And Closed Cell Therapy Processing Systems Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow
  • 6.2.2. By Type
  • 6.2.3. By Scale
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Scale
  • 6.3.2. Canada Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Scale
  • 6.3.3. Mexico Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Scale

7. Europe Automated And Closed Cell Therapy Processing Systems Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow
  • 7.2.2. By Type
  • 7.2.3. By Scale
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Scale
  • 7.3.2. France Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Scale
  • 7.3.3. United Kingdom Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Scale
  • 7.3.4. Italy Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Scale
  • 7.3.5. Spain Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Scale

8. Asia Pacific Automated And Closed Cell Therapy Processing Systems Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow
  • 8.2.2. By Type
  • 8.2.3. By Scale
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Scale
  • 8.3.2. India Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Scale
  • 8.3.3. Japan Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Scale
  • 8.3.4. South Korea Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Scale
  • 8.3.5. Australia Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Scale

9. Middle East & Africa Automated And Closed Cell Therapy Processing Systems Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow
  • 9.2.2. By Type
  • 9.2.3. By Scale
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Scale
  • 9.3.2. UAE Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Scale
  • 9.3.3. South Africa Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Scale

10. South America Automated And Closed Cell Therapy Processing Systems Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow
  • 10.2.2. By Type
  • 10.2.3. By Scale
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Scale
  • 10.3.2. Colombia Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Scale
  • 10.3.3. Argentina Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Scale

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Automated And Closed Cell Therapy Processing Systems Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Miltenyi Biotec B.V. & Co. KG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group AG
• 15.3. Fresenius Kabi AG
• 15.4. Global Life Sciences Solutions USA LLC
• 15.5. BioSpherix, LLC
• 15.6. Terumo Corp
• 15.7. Sartorius AG
• 15.8. ThermoGenesis Holdings Inc
• 15.9. Cellares Corporation
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer